FDA Approves Long-Acting Recombinant Factor IX > Publications

FDA Approves Long-Acting Recombinant Factor IX

Published April 9, 2014

By Leigh Carpenter, RPh, Director of Pharmacy

Biogen Idec received FDA approval for Alprolix on March 28th. The long-acting recombinant factor IX product will be available for hemophilia B patients and promises an extended half-life by using a type of fusion technology. The initial assay sizes available will be in the 500, 1000, 2000 and 3000 international units range. Please be on the look-out for a more in-depth article in next month’s newsletter. Our pharmacies will carry the new product once Biogen Idec begins shipping. If you are interested in this new product, please contact your HTC staff to discuss obtaining a prescription for Alprolix.